UBS O'Connor’s Moderna MRNA Stock Holding History

UBS O'Connor’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-28,000	Closed	-$237K	–	570
2024 Q2	$237K	Buy	+28,000	New	+$3.54M	0.01%	413

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

UBS O'Connor's MRNA Position: Q4 2021 in Review

UBS O'Connor sold out of Moderna (MRNA) in Q4 2021, closing a stake of 7,500 shares — an estimated $2.89M sold.

UBS O'Connor first reported a position in MRNA in Q2 2021 and held it in 2 quarters. The position peaked at $2.89M in Q3 2021. 1,109 funds tracked by Wall St. Rank hold MRNA as of Q4 2021.

UBS O'Connor reported no remaining Moderna position as of Q4 2021 after selling out during the quarter.
UBS O'Connor sold 7,500 Moderna shares in Q4 2021, an estimated $2.89M.
UBS O'Connor first reported a position in Moderna in Q2 2021 and held it in 2 quarters.
UBS O'Connor's Moderna position peaked at $2.89M in Q3 2021.
1,109 funds tracked by Wall St. Rank held Moderna as of Q4 2021.

Based on UBS O'Connor's 13F filing for Q4 2021, filed 14 Feb 2022.